| Total examined, n | MGMT methylated and lost (%) | p Value | |
| MSI status | |||
| MSI-high | 91 | 29 (32%) | |
| MSI-low | 46 | 19 (41%) | 0.02 |
| MSS | 421 | 106 (25%) | Referent |
| CIMP status | |||
| CIMP-high | 101 | 35 (35%) | 0.005 |
| CIMP-low | 199 | 66 (33%) | 0.002 |
| CIMP-0 | 267 | 55 (21%) | Referent |
| KRAS | |||
| Any mutation | 197 | 65 (33%) | 0.03 |
| G>A mutation | 127 | 45 (35%) | 0.02 |
| Non-G>A mutation | 70 | 20 (29%) | |
| Wild-type | 349 | 85 (24%) | Referent |
| KRAS/BRAF | |||
| K(+)B(+) | 3 | 2 (67%) | |
| K(+)B(−) | 194 | 63 (32%) | 0.04 |
| K(−)B(+) | 76 | 15 (20%) | Referent |
| K(−)B(−) | 273 | 70 (26%) | |
| 18q LOH | |||
| (+) | 163 | 28 (17%) | 0.0002 |
| (−) | 142 | 51 (36%) | Referent |
Only statistically significant p values are described. CIMP, CpG island methylator phenotype; LOH, loss of heterozygosity; MSI, microsatellite instability; MSS, microsatellite stable.